Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DVS SR for Vasomotor Symptoms in Menopause
NCT00683800Phase 3Completed
- Sponsor
- Pfizer
- Start
- Jun 2008
- Primary completion
- May 2010
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in vasomotor symptoms comparing desvenlafaxine succinate (DVS) SR with Placebo (2 arms). Primary endpoints: Change From Baseline in the Average Daily Number of Moderate to Severe Hot Flushes at Week 4, Change From Baseline in the Average Daily Number of Moderate to Severe Hot Flushes at Week 12 and 3 more. Started Jun 2008; status: completed.
02
Drugs
desvenlafaxine
03
Conditions
vasomotor symptoms
Beyond the preview
Go deeper on NCT00683800.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00683800.